For molecular transplant, respiratory, and sexual health testing department of pathology and area laboratory services
Active Definitive Contract Awarded Last action
- Contract number
- W81K0025CA008
- Awardee
-
Abbott Molecular Inc. UEI NK5QDVJBHMN7
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $1,239,477
Award facts
- Opportunity
-
- RT-PCR Molecular Testing for Transplant, Respiratory, and Sexual Health Infections Department of Pathology and Area Laboratory Services (DPALS) Pre-Solicitation · W81K0025QA037 · Posted Dec 5, 2024
- Contract value 21% obligated
-
- $2,761,265.16 Current, with exercised options
- $5,804,820.62 Potential, with all options
- Completion date 2% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- JBSA FT SAM HOUSTON, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Change Order | $33,531 | |
| Funding Only Action | -$315,848 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $1,521,794 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a $5.8 million definitive contract to Abbott Molecular Inc. for molecular transplant, respiratory, and sexual health testing services at Brooke Army Medical Center on October 1, 2026, with performance through September 30, 2029.
The originating pre-solicitation, posted December 5, 2024, sought FDA-approved random-access multiplex RT-PCR testing platforms capable of processing viral load, HPV, sexually transmitted infection, and respiratory panel tests, including comprehensive screening for Hepatitis B/C, HIV-1, Cytomegalovirus, and COVID-19. The procurement requires minimum throughput of 300 tests per 8-hour shift, MHS Genesis connectivity, uninterruptible power supply, and 24/7 technical support with 24-hour repair response time. The contract is structured as a cost-per-test agreement with the contractor providing all equipment, reagents, consumables, controls, maintenance, and training. Performance is based at JBSA FT SAM HOUSTON, TX. The base period runs October 1, 2025 through September 30, 2026, with three additional one-year option periods extending through September 30, 2029. Annual testing volumes range from 1,152 tests for certain viral screenings to 60,672 tests for HPV screening. The contract serves as the sole evaluation site for U.S. Air Force and Army HIV testing. No set-aside was used; the incumbent, Roche, was excluded from consideration.
Quick answers
Who was awarded contract W81K0025CA008?
W81K0025CA008 was awarded to Abbott Molecular Inc. by Medical Command (Department of the Army) on October 1, 2026.
How much is contract W81K0025CA008 worth?
The government has obligated $1,239,477 on W81K0025CA008. Its current value, with exercised options, is $2,761,265. Its potential value, with all options, is $5,804,821.
Which agency awarded contract W81K0025CA008?
Medical Command (Department of the Army) awarded W81K0025CA008, with funding from Defense Health Agency (Department of Defense).
Was contract W81K0025CA008 competed?
The extent of competition for W81K0025CA008 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award